**Outpatient Medical Injectable**
**Vyepti Authorization Request Form**
**Fax to 833-581-1861**
**(Medical Benefit Only)**

Member Name: _____DOB: _____

Member ID (UMI): _____ ☐ Medicare ☐ Commercial

Address: _____

**ORDERING/ATTENDING PROVIDER**

Physician Name: _____ NPI: _____

Address: _____

Office Contact: _____ Phone Number: _____Fax Number: _____

**SITE OF CARE**

**Place of Service *(please select one)***

☐ Home Infusion ☐ Office – Professional ☐ Ambulatory Infusion Suite – Professional ☐ Outpatient Hospital

Is the site of care affiliated with a hospital or will the claim be billed as a facility claim? ☐ Yes ☐ No

Place of Service Name: _____ NPI: _____ Tax ID: _____

Address: _____

**Drug Supplier *(please select one)***

☐ Supplied by a Specialty Pharmacy *(for Home Infusion, Office – Professional, or Ambulatory Infusion Suite – Professional)*

☐ Buy & Bill *(for Office – Professional or Outpatient Hospital administration)*

Pharmacy Name: _____ Pharmacy NPI: _____

**DRUG/DIAGNOSIS INFORMATION**

## VYPETI (J3032)

ICD10 Diagnosis Code(s): _____ Diagnosis Code Description: _____

Dose: _____ Frequency: _____ Number of visits requested: _____ Date of Service: _____

| **CLINICAL INFORMATION** |
|---|
| How many days per month does the member experience *headache*? |
| How many days per month does the member experience *migraine*? |

****Please verify member's eligibility and benefits through the health plan****

| |
|---|
| Are headaches caused by medication rebound or lifestyle issues? ☐ YES ☐ NO |
| Is this request prescribed by or in consultation with a neurologist or headache specialist? ☐ YES ☐ NO |
| Has the member tried and failed adequate trials of prophylactic therapy from at least two different therapy classes (ex: antiseizure, beta blocker, tricyclic antidepressant)? ☐ YES ☐ NO<br>• Please list all previous prophylactic therapies tried and failed, not tolerated or contraindicated:<br>_____<br>_____ |
| If the treatment plan is to use two chemically distinct CGRP inhibitors in combination for preventive and acute use, does the prescriber attest the benefits of therapy outweigh the risks of concurrent use of both medications? ☐ YES ☐ NO |

| ☐ **New Start** | ☐ **Continuation of Therapy**<br><br>Date of last infusion: _____<br><br>• Has the member had a reduction in the number of migraine days per month by at least 50% from baseline? ☐ YES ☐ NO<br><br>• The member has had a reduction in migraine days per month by at least_____ days from baseline |
|---|---|

**Please attach all pertinent clinical information**

**Attached:** ☐ **YES** ☐ **NO**

This information is issued on behalf of Highmark Blue Shield and its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association. Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in 21 counties in central Pennsylvania and 13 counties in northeastern New York. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania. Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware, and 8 counties in western New York. All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies.